Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: A comparative prospective clinical trial
CONCLUSION: In patients with renal failure, sugammadex (4 mg kg−1) effectively and safely reversed profound rocuronium induced neuromuscular block, but the recovery was slower than healthy patients.
TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT01785758.
Source: European Journal of Anaesthesiology - Category: Anesthesiology Tags: Neuromuscular blocking agents Source Type: research
More News: Anesthesia | Anesthesiology | Clinical Trials | Drugs & Pharmacology | Kidney Transplant | Kidney Transplantation | Neurology | Neurosurgery | Renal Failure | Skin | Study | Transplant Surgery | Transplants | Urology & Nephrology